<DOC>
	<DOC>NCT02194309</DOC>
	<brief_summary>To investigate safety, tolerability, and pharmacokinetics of telmisartan and amlodipine following single administration of 40 mg telmisartan/5 mg amlodipine and 80 mg telmisartan/5 mg amlodipine, and subsequently, following multiple administration of 40 mg telmisartan/5 mg amlodipine and 80 mg telmisartan/5 mg amlodipine once daily for 10 days</brief_summary>
	<brief_title>Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Healthy male volunteers according to the following criteria: 1. No finding deviating of clinical relevance and no evidence of a clinically relevant concomitant disease based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate, body temperature), 12lead ECG, clinical laboratory tests 2. Age ≥20 and Age ≤35 years 3. Body weight ≥50 kg 4. Body mass index (BMI) ≥17.6 and BMI ≤26.4 kg/m2 5. Signed and dated written informed consent before admission to the trial 1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders 2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders 3. Chronic or relevant acute infections 4. Any clinical relevant findings of the laboratory test deviating from normal 5. Positive result for either hepatitis B surface antigen (HBsAg), anti hepatitis C virus (HCV) antibodies, syphilitic test or human immunodeficiency virus (HIV) test 6. History of surgery of gastrointestinal tract (except appendectomy) 7. History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varied by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varied by ≥10 mmHg from mean supine DBP), fainting spells or blackouts 8. History of hepatic dysfunction (e.g., biliary cirrhosis, cholestasis) 9. History of serious renal dysfunction 10. History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney 11. History of cerebrovascular disorder 12. History of hyperkalemia 13. Known hypersensitivity to any component of the formulation, or to any other Angiotensin Receptor Blocker (ARB), angiotensin converting enzyme or dihydropyridine 14. Intake of drugs with a long halflife (≥24 hours) within at least one month or less than 10 halflives of the respective drug before administration or during the trial 15. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days before administration or during the trial 16. Participation in another trial with an investigational drug within 4 months or 6 halflives of the investigational drug before administration 17. Smoker (≥20 cigarettes/day) 18. Alcohol abuse (60 g or more ethanol/day: ex. 3 middlesized bottles of beer, 3 gous (equivalent to 540 mL) of sake) 19. Drug abuse 20. Blood donation (more than 100 mL within 4 weeks before administration or during the trial) 21. Excessive physical activities (within 1 week before administration or during the trial) 22. Intake of alcohol within 2 days before administration 23. Inability to comply with dietary regimen of trial centre 24. Intake of any drugs/supplements with ingredient of hypericum perforatum (citrus fruits, Sevilla orange) within 5 days prior to administration 25. Inability to refrain from smoking on trial days</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>